GLP-1 Users' diets under the microscope: what are they really eating?

NCT ID NCT07313384

Ongoing Knowledge-focused Sponsor: University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study follows 50 adults who are about to start GLP-1 therapy for obesity or type 2 diabetes. Researchers will track how their eating habits change over 12 weeks using diet quality scores and body weight. The goal is to understand what dietary support people need while on these medications, since current guidance focuses mostly on cutting calories rather than ensuring good nutrition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 therapy (a class of medications for obesity or type 2 diabetes)
What this could lead to: If successful, this study could help develop better dietary guidelines and support programs for people taking GLP-1 medications.
What could go wrong: This is a small observational study (50 people) that does not test a new treatment. It only looks at eating habits, so it cannot prove whether any diet changes improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY (DISORDER) OBESITY TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Prisma Health Weight Management Institute

Greenville, South Carolina, 29607, United States
University South Carolina

Columbia, South Carolina, 20208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.